Top

Published in:

01-06-2015

Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer

Authors: Yong Zhang, Haiyun Wang, Jian Wang, Lianming Bao, Lingyan Wang, Jiayuan Huo, Xiangdong Wang

Published in: Cancer and Metastasis Reviews | Issue 2/2015

Abstract

The present study aimed at investigating genetic variations, specific signal pathways, or biological processes of chromosome 1 genes between subtypes and stages of lung cancer and prediction of selected targeting genes for patient survival rate. About 537 patients with lung adenocarcinoma (ADC), 140 with lung squamous carcinoma (SCC), 9 with lung large-cell carcinoma (LCC), 56 with small-cell lung cancer (SCLC), and 590 without caner were integrated from 16 databases and analyzed in the present study. Three (ASPM, CDC20, KIAA1799) or 28 genes significantly up- or down-expressed in four subtypes of lung cancer. The activated cell division and down-regulated immune responses were identified in patients with lung cancer. Keratinocyte development associated genes S100 and SPRR families dominantly up-expressed in SCC and AKT3 and NRAS in SCLC. Subtype-specific genes of ADC, SCC, LCC, or SCLC were also identified. C1orf106, CAPN8, CDC20, COL11A1, CRABP2, and NBPF9 up-expressed at four stages of ADC. Fifty six related with keratinocytes or potassium channels up-expressed in three stages of SCC. CDC20, IL10, ECM1, GABPB2, CRABP2, and COL11A1 significantly predicted the poor overall survival of ADC patients and S100A2 and TIMM17A in SCC patients. Our data indicate that a number of altered chromosome 1 genes have the subtype and stage specificities of lung cancer and can be considered as diagnostic and prognosis biomarkers.

Available only for authorised users

Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69–90.

Hensing, T., Chawla, A., Batra, R., & Salgia, R. (2014). A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in Experimental Medicine and Biology, 799, 85–117.PubMedCrossRef

Oxnard, G. R., Binder, A., & Janne, P. A. (2013). New targetable oncogenes in non-small-cell lung cancer. Journal of Clinical Oncology, 31, 1097–1104.PubMedCentralPubMedCrossRef

Baty, F., Facompre, M., Kaiser, S., et al. (2010). Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 181, 181–188.PubMedCrossRef

Sanchez-Palencia, A., Gomez-Morales, M., Gomez-Capilla, J. A., et al. (2011). Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. International Journal of Cancer, 129, 355–364.CrossRef

Kuner, R., Muley, T., Meister, M., et al. (2009). Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer, 63, 32–38.PubMedCrossRef

Takeuchi, T., Tomida, S., Yatabe, Y., et al. (2006). Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. Journal of Clinical Oncology, 24, 1679–1688.PubMedCrossRef

Lockwood, W. W., Chari, R., Coe, B. P., et al. (2008). DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene, 27, 4615–4624.PubMedCentralPubMedCrossRef

Stella, G. M., Luisetti, M., Pozzi, E., & Comoglio, P. M. (2013). Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respiratory Medecine, 1, 251–261.CrossRef

10.

Barrett, T., Troup, D. B., Wilhite, S. E., et al. (2007). NCBI GEO: mining tens of millions of expression profiles—database and tools update. Nucleic Acids Research, 35, D760–D765.PubMedCentralPubMedCrossRef

11.

Huang, Z. X., Tian, H. Y., Hu, Z. F., Zhou, Y. B., Zhao, J., & Yao, K. T. (2008). GenCLiP: a software program for clustering gene lists by literature profiling and constructing gene co-occurrence networks related to custom keywords. BMC Bioinformatics, 9, 308.PubMedCentralPubMedCrossRef

12.

Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y., & Hattori, M. (2004). The KEGG resource for deciphering the genome. Nucleic Acids Research, 32, D277–D280.PubMedCentralPubMedCrossRef

13.

Therneau, T. (2014). A package for survival analysis in S. R package version 2.37-7, http://CRAN.R-project.org/package=survival.

14.

Gyorffy, B., Surowiak, P., Budczies, J., & Lanczky, A. (2013). Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One, 8, e82241.PubMedCentralPubMedCrossRef

15.

Gregory, S. G., Barlow, K. F., McLay, K. E., et al. (2006). The DNA sequence and biological annotation of human chromosome 1. Nature, 441, 315–321.PubMedCrossRef

16.

Nilsson, J., Yekezare, M., Minshull, J., & Pines, J. (2008). The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nature Cell Biology, 10, 1411–1420.PubMedCentralPubMedCrossRef

17.

Kato, T., Daigo, Y., Aragaki, M., Ishikawa, K., Sato, M., & Kaji, M. (2012). Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. Journal of Surgical Oncology, 106, 423–430.PubMedCrossRef

18.

Bond, J., Roberts, E., Mochida, G. H., et al. (2002). ASPM is a major determinant of cerebral cortical size. Nature Genetics, 32, 316–320.PubMedCrossRef

19.

Higgins, J., Midgley, C., Bergh, A. M., et al. (2010). Human ASPM participates in spindle organisation, spindle orientation and cytokinesis. BMC Cell Biology, 11, 85.PubMedCentralPubMedCrossRef

20.

Finger, E. C., Turley, R. S., Dong, M., How, T., Fields, T. A., & Blobe, G. C. (2008). TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis, 29, 528–535.PubMedCrossRef

21.

Wei, S., Wang, H., Lu, C., et al. (2014). The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins. Journal of Biological Chemistry, 289, 8947–8959.PubMedCentralPubMedCrossRef

22.

Samten, B. (2013). CD52 as both a marker and an effector molecule of T cells with regulatory action: identification of novel regulatory T cells. Cellular and molecular immunology, 10, 456–458.PubMedCentralPubMedCrossRef

23.

Shen, B., Yu, H., Hao, X., Qu, L., Cai, X., & Li, N. (2013). Impact of antimouse CD52 monoclonal antibody on graft’s gammadelta intraepithelial lymphocytes after orthotopic small bowel transplantation in mice. Transplantation, 95, 663–670.PubMedCrossRef

24.

Shipman, M., Lubick, K., Fouchard, D., et al. (2012). Proteomic and systems biology analysis of monocytes exposed to securinine, a GABA(A) receptor antagonist and immune adjuvant. PLoS One, 7, e41278.PubMedCentralPubMedCrossRef

25.

Cha, I. S., Castillo, C. S., Nho, S. W., Hikima, J., Aoki, T., & Jung, T. S. (2011). Innate immune response in the hemolymph of an ascidian, Halocynthia roretzi, showing soft tunic syndrome, using label-free quantitative proteomics. Developmental and Comparative Immunology, 35, 809–816.PubMedCrossRef

26.

Park, I. H., Park, S. J., Cho, J. S., et al. (2012). Increased expression of intelectin-1 in nasal polyps. American Journal of Rhinology & Allergy, 26, 274–277.CrossRef

27.

Park, J. C., Chae, Y. K., Son, C. H., et al. (2008). Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochemical and Biophysical Research Communications, 365, 221–226.PubMedCrossRef

28.

Chong, I. W., Chang, M. Y., Chang, H. C., et al. (2006). Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncology Reports, 16, 981–988.PubMed

29.

Roche, J., Nasarre, P., Gemmill, R., et al. (2013). Global decrease of histone H3K27 acetylation in ZEB1-induced epithelial to mesenchymal transition in lung cancer cells. Cancers (Basel), 5, 334–356.CrossRef

30.

Jo, U., Park, K. H., Whang, Y. M., et al. (2014). EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR. Oncotarget, 5, 1265–1278.PubMedCentralPubMed

31.

Sundarraj, S., Kannan, S., Thangam, R., & Gunasekaran, P. (2012). Effects of the inhibition of cytosolic phospholipase A(2)alpha in non-small cell lung cancer cells. Journal of Cancer Research and Clinical Oncology, 138, 827–835.PubMedCrossRef

32.

Salama, I., Malone, P. S., Mihaimeed, F., & Jones, J. L. (2008). A review of the S100 proteins in cancer. European Journal of Surgical Oncology, 34, 357–364.PubMedCrossRef

33.

Naz, S., Bashir, M., Ranganathan, P., Bodapati, P., Santosh, V., & Kondaiah, P. (2014). Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3. Carcinogenesis, 35, 14–23.PubMedCrossRef

34.

Tsuta, K., Tanabe, Y., Yoshida, A., et al. (2011). Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. Journal of Thoracic Oncology, 6, 1190–1199.PubMedCrossRef

35.

Vermeij, W. P., & Backendorf, C. (2010). Skin cornification proteins provide global link between ROS detoxification and cell migration during wound healing. PLoS One, 5, e11957.PubMedCentralPubMedCrossRef

36.

Woenckhaus, M., Klein-Hitpass, L., Grepmeier, U., et al. (2006). Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. Journal of Pathology, 210, 192–204.PubMedCrossRef

37.

Fujii, S. I., Shimizu, K., Okamoto, Y., et al. (2013). NKT cells as an ideal Anti-tumor immunotherapeutic. Frontiers in Immunology, 4, 409.PubMedCentralPubMedCrossRef

38.

Declerck, S., & Vansteenkiste, J. (2014). Immunotherapy for lung cancer: ongoing clinical trials. Future Oncology, 10, 91–105.PubMedCrossRef

39.

Mollbrink, A., Jawad, R., Vlamis-Gardikas, A., et al. (2014). Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome. International Journal of Immunopathology and Pharmacology, 27, 169–183.PubMed

40.

Su, D. M., Zhang, Q., Wang, X., et al. (2009). Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Molecular Cancer Therapeutics, 8, 1292–1304.PubMedCentralPubMedCrossRef

41.

Salio, M., Silk, J. D., Jones, E. Y., & Cerundolo, V. (2014). Biology of CD1- and MR1-restricted T cells. Annual Review of Immunology, 32, 323–366.PubMedCrossRef

42.

Umemura, S., Mimaki, S., Makinoshima, H., et al. (2014). Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. Journal of Thoracic Oncology, 9, 1324–1331.PubMedCentralPubMedCrossRef

43.

Zitzmann, K., Vlotides, G., Brand, S., et al. (2012). Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocrine-Related Cancer, 19, 423–434.PubMedCrossRef

44.

Ohashi, K., Sequist, L. V., Arcila, M. E., et al. (2013). Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research, 19, 2584–2591.PubMedCentralPubMedCrossRef

45.

Kim, B. H., Shenoy, A. R., Kumar, P., Das, R., Tiwari, S., & MacMicking, J. D. (2011). A family of IFN-gamma-inducible 65-kD GTPases protects against bacterial infection. Science, 332, 717–721.PubMedCrossRef

46.

Aoyama, D., Hashimoto, N., Sakamoto, K., et al. (2013). Involvement of TGFbeta-induced phosphorylation of the PTEN C-terminus on TGFbeta-induced acquisition of malignant phenotypes in lung cancer cells. PLoS One, 8, e81133.PubMedCentralPubMedCrossRef

47.

Hill, K. S., Erdogan, E., Khoor, A., et al. (2013). Protein kinase Calpha suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFbeta signaling axis. Oncogene. doi:10.1038/onc.2013.147.

Title: Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer
Authors: Yong Zhang
Haiyun Wang
Jian Wang
Lianming Bao
Lingyan Wang
Jiayuan Huo
Xiangdong Wang
Publication date: 01-06-2015
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9558-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Biographies

Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases

Global analyses of subtype- or stage-specific genes on chromosome 7 in patients with lung cancer

Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

Detecting disease genes of non-small lung cancer based on consistently differential interactions

Epigenetics in lung cancer diagnosis and therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer